← Back to Search

Hormone Therapy

MP-101 for Obesity

Phase 2
Waitlist Available
Research Sponsored by Manhattan Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be a male or female between the ages of 18 and 65 years
Female subjects must be either surgically sterile or at least 2 years postmenopausal
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial will study the safety and effectiveness of a new drug for obesity in 100 adults.

Who is the study for?
This trial is for adults aged 18-65 with obesity, having a BMI of 27-38.9, who are generally healthy and have stable weight and lifestyle habits (like smoking and exercise). Women must be postmenopausal or surgically sterile. Participants should not have been dieting recently, work night shifts, or have significant medical conditions.Check my eligibility
What is being tested?
The study tests the safety and initial effectiveness of MP-101 in obese individuals over two cycles of escalating oral doses for 14 days each. It also looks at how the body processes the drug.See study design
What are the potential side effects?
While specific side effects aren't listed here, common ones may include digestive issues, changes in appetite or metabolism, fatigue, headaches or other bodily discomforts typically associated with new medications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 65 years old.
Select...
I am a woman who is either surgically sterile or have been menopausal for at least 2 years.
Select...
My BMI is between 27 and 38.9.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To evaluate the safety and tolerability
Secondary outcome measures
To evaluate the preliminary efficacy

Find a Location

Who is running the clinical trial?

Manhattan PharmaceuticalsLead Sponsor
2 Previous Clinical Trials
85 Total Patients Enrolled
1 Trials studying Obesity
24 Patients Enrolled for Obesity

Media Library

MP-101 (Hormone Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT00449202 — Phase 2
Obesity Research Study Groups:
Obesity Clinical Trial 2023: MP-101 Highlights & Side Effects. Trial Name: NCT00449202 — Phase 2
MP-101 (Hormone Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00449202 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are patients being enrolled in this clinical trial at this time?

"This particular clinical trial is no longer recruiting patients, as stated on the website clinicaltrials.gov. The study was first posted on June 1st 2006 but has not been updated since March 16th 2007. Although this specific trial has completed recruitment, there are still 999 other trials that are actively looking for participants."

Answered by AI

Have federal regulators given this medication their blessing?

"This treatment received a score of 2 for safety. While there is some evidence backing its safety, no data currently supports efficacy claims."

Answered by AI

Do patients of all ages qualify to enroll in this research?

"This trial is looking for 100 people, within the ages of 18 and 65 who have obesity. It is required that patients also meet the following criteria: Be a male or female between the ages of 18 and 65 years, inclusive, Female subjects must be either surgically sterile or at least 2 years postmenopausal, Have a BMI of 27 - 38.9, inclusive, Have a stable weight for the past 30 days per subject report, Be otherwise healthy and have an acceptable medical history, Exhibit stable behavior patterns with regard to smoking and exercise, Subject who has at least one factor of the metabolic syndrome."

Answered by AI

Would patients outside the age group of 40 still be eligible for this clinical trial?

"The age range for this clinical trial is from 18 to 65. If the patient does not fit that criteria, there are 617 other studies for patients over 65 and 208 for those under 18."

Answered by AI

Who else is applying?

What state do they live in?
Louisiana
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
What site did they apply to?
Jean Brown Research
Pennington Biomedical Research
How many prior treatments have patients received?
0

Why did patients apply to this trial?

I have tried multiple ways to lose weight. I need help. I've been on a restricted medical diet and consistent exercise program with no weight loss.
PatientReceived 1 prior treatment
I've been on a restricted medical diet and consistent exercise program with no weight loss. Past blood work suggests I'm insulin resistant/pre-diabetic.
PatientReceived no prior treatments

What questions have other patients asked about this trial?

Is there a placebo?
PatientReceived 2+ prior treatments
Recent research and studies
clinicaltrials.govStudy
Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone (MP-101)
2006. "Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone (MP-101)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00449202.
All > Obesity
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top